Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
221 hedge funds and large institutions have $2.98B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2018 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 65 increasing their positions, 85 reducing their positions, and 28 closing their positions.
192% more call options, than puts
Call options by funds: $22.4M | Put options by funds: $7.67M
61% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 28
22% more capital invested
Capital invested by funds: $2.44B → $2.98B (+$532M)
8% more funds holding
Funds holding: 204 → 221 (+17)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
24% less repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 85
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$54.2M |
| 2 |
Jennison Associates
New York
|
+$26.9M |
| 3 |
D.E. Shaw & Co
New York
|
+$24.3M |
| 4 |
Renaissance Technologies
New York
|
+$19.1M |
| 5 |
Morgan Stanley
New York
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$21.5M |
| 2 |
BC
Broadfin Capital
New York
|
-$17.7M |
| 3 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$15.8M |
| 4 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
-$13.6M |
| 5 |
PC
Paulson & Co
New York
|
-$9.51M |
HZNP Hedge Fund Activity: Q3 2018 in Review
221 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q3 2018, worth a combined $2.98B — up 22% from $2.44B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new HZNP positions and 28 closed out — a net gain of 17 holders — while 65 added to existing stakes and 85 trimmed.
The largest buyer was Scopia Capital Management, adding an estimated $54.2M. The largest seller was Avoro Capital Advisors, cutting an estimated $21.5M.
- 221 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q3 2018, up from 204 in Q2 2018.
- Funds reported $2.98B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q3 2018, up 22% quarter-over-quarter.
- 45 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q3 2018 and 28 closed out, a net change of +17 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q3 2018 was Scopia Capital Management, an estimated $54.2M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q3 2018 was Avoro Capital Advisors, an estimated $21.5M sold.
Based on aggregated 13F filings for Q3 2018.